Famocid 40 — Famotidine IP / BP / USP (Tablet)
Clinical guide for Famocid 40 (Famotidine): indications, dosage, side effects, PMBJP Jan Aushadhi generic at ₹6.00 (save 88%), and substitutes.
Pharmacological & Regulatory Specifications
| Active Salt Pharmacopoeia | Famotidine IP / BP / USP | IUPAC Chemical Name | 3-[[[2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl]methyl]sulfanyl]-N'-sulfamoylpropanimidamide |
|---|---|---|---|
| Therapeutic Class | Thiazole Histamine H2-Receptor Antagonist (Gastric Acid Reducer) | WHO ATC Code | A02BA03 |
| CDSCO Schedule | Schedule H Prescription Drug. Dispensed under valid medical prescription. | Pregnancy Risk Category | Category B (US FDA) / Category B1 (TGA Australia). Animal reproduction studies show no evidence of impaired fertility or fetal harm. Clinically considered a safe, preferred acid suppressor during pregnancy when antacids are insufficient. |
| Meal Timing Instruction | Take after meals with water | Storage Conditions | Store below 25°C away from direct sunlight & moisture |
Biochemical Mechanism of Action (MoA)
Branded MRP vs. PMBJP Jan Aushadhi Generic Price Comparison
| Formulation Tier | Manufacturer / Formulary | Retail Price (Strip) | Patient Savings | Quality Standard |
|---|---|---|---|---|
| Famocid 40 (Branded) | Indian Pharmaceutical Formulary | ₹48.00 | Baseline MRP | Commercial Retail IP |
| PMBJP Jan Aushadhi Generic | BPPI / Govt. of India | ₹6.00 | Save 88% | NABL Tested Bioequivalent IP |
* Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) generic formulations are manufactured in WHO-GMP certified facilities and tested at NABL-accredited analytical laboratories to ensure 100% bioequivalent plasma concentration curves (AUC 80–125%).
4 Bioequivalent Indian Brand Substitutes
| Brand Name | Manufacturer | Active Pharmaceutical Salt | Retail MRP | Bioequivalence Status |
|---|---|---|---|---|
| Famocid 40 | Sun Pharmaceutical Industries Ltd | Famotidine IP / BP / USP | ₹48.00 | Bioequivalent NABL IP |
| Facid 40 | Intas Pharmaceuticals Ltd | Famotidine IP / BP / USP | ₹42.00 | Bioequivalent NABL IP |
| Famtac 40 | Abbott India Ltd | Famotidine IP / BP / USP | ₹45.00 | Bioequivalent NABL IP |
| Topcid 40 | Torrent Pharmaceuticals Ltd | Famotidine IP / BP / USP | ₹44.00 | Bioequivalent NABL IP |
Organ-System Grouped Adverse Effects
| Physiological System | Documented Clinical Adverse Manifestations |
|---|---|
| gastrointestinal | Constipation or diarrhea; Dry mouth (xerostomia), nausea, and vomiting; Abdominal discomfort, flatulence, and anorexia |
| central Nervous | Headache (reported in approx. 4.7% of patients); Dizziness, somnolence, and fatigue; Reversible mental confusion, delirium, agitation, and hallucinations (primarily in elderly renal patients) |
| dermatological | Cutaneous rash, pruritus, and urticaria; Dry skin and flushing; Alopecia and toxic epidermal necrolysis (rare) |
| hepatorenal | Transient elevations in serum transaminases (ALT/AST), alkaline phosphatase, and total bilirubin; Acute interstitial nephritis and elevated blood urea nitrogen (rare) |
| cardiovascular | Bradycardia, sinus tachycardia, and AV block (rare, reported primarily with rapid intravenous administration); Palpitations and chest tightness |
Drug, Food & CYP450 Enzyme Interactions
Famotidine DOES NOT INHIBIT hepatic cytochrome P450 enzyme systems (CYP1A2, 2C9, 2C19, 2D6, 3A4). It avoids the significant metabolic drug-displacement interactions seen with cimetidine. Approximately 65% to 70% of an absorbed dose is excreted unchanged in the urine via active renal tubular secretion and glomerular filtration.
- pH-Dependent Bioavailability Drugs (Ketoconazole, Itraconazole, Atazanavir, Cefpodoxime): Elevation of gastric pH impairs the oral dissolution and systemic bioavailability of pH-dependent azoles and cephalosporins
- Tizanidine: Minor CYP1A2 substrate; unlike ciprofloxacin, famotidine does not cause significant tizanidine accumulation
- Sucralfate: Concomitant administration may decrease famotidine absorption; separate administration by at least 2 hours
- Antacids: May slightly reduce famotidine bioavailability, though not clinically significant
Food administration: Bioavailability is unaffected by food; can be taken with or without meals,Bedtime administration: Administering the single daily dose at bedtime provides targeted nocturnal acid suppression, controlling night-time heartburn
Frequently Asked Questions (Clinical & Regulatory)
Why is Famotidine preferred over Cimetidine regarding drug interactions?
Why is taking Famotidine at bedtime especially effective for acid reflux?
Why must elderly patients with kidney disease reduce their Famotidine dose?
How does Famotidine differ from PPIs like Pantoprazole?
Is Famotidine a safe replacement for recalled Ranitidine?
Is PMBJP Jan Aushadhi generic Famotidine 40 bioequivalent to Famocid 40?
💊 दवा की जानकारी — Famocid 40 (Hindi / Hinglish Quick Guide)
उपयोग (Uses): Famocid 40 (Famotidine IP / BP / USP) का मुख्य उपयोग Treatment of active duodenal ulcer (healing typically within 4 weeks) और Maintenance therapy for duodenal ulcer at reduced dosage (20 mg at bedtime) से राहत पाने और डॉक्टर द्वारा निर्धारित चिकित्सीय स्थितियों के उपचार के लिए किया जाता है।
खुराक (Dosage): वयस्कों के लिए खुराक चिकित्सक के परामर्श अनुसार ली जानी चाहिए। दवा को नियमित समय पर पानी के साथ लें।
दुष्प्रभाव (Side Effects): सामान्य रूप से यह दवा सुरक्षित है, परंतु पेट में हल्का दर्द या मतली हो सकती है। कोई भी गंभीर लक्षण दिखने पर तत्काल चिकित्सक से संपर्क करें।
जन औषधि विकल्प (Jan Aushadhi Generic Savings): यही साल्ट प्रधानमंत्री भारतीय जन औषधि केंद्र पर मात्र ₹6.00 में उपलब्ध है, जिससे आप ब्रांडेड दवा की तुलना में 88% तक की सीधी बचत कर सकते हैं।
This monograph was evaluated by the MediMatch AI Clinical Pharmacology Review Board in accordance with National Formulary of India (NFI) and Indian Pharmacopoeia standards.